Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
TG Therapeutics, Inc. - Common Stock
(NQ:
TGTX
)
35.44
+1.14 (+3.32%)
Streaming Delayed Price
Updated: 12:43 PM EDT, Apr 17, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about TG Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
12
13
Next >
TG Therapeutics Inc (NASDAQ:TGTX): An Affordable Growth Stock with Strong Momentum
↗
April 04, 2026
Via
Chartmill
What to Know About This Obesity Drug Developer That Just Drew a New $7 Million Investment
↗
March 16, 2026
Viking Therapeutics develops clinical-stage therapies for metabolic and endocrine disorders, aiming to address unmet medical needs.
Via
The Motley Fool
Topics
Regulatory Compliance
This Biotech With a Breakout MS Drug Draws $8 Million Investment Amid 30% Stock Drop
↗
March 16, 2026
This biopharma firm develops therapies for B-cell malignancies and autoimmune diseases, with a focus on oncology and immunology.
Via
The Motley Fool
TG Therapeutics Inc (NASDAQ:TGTX) Presents a Compelling Momentum Case with Strong Growth and Technical Setup
↗
March 14, 2026
Via
Chartmill
TG Therapeutics (TGTX) Q4 2025 Earnings Transcript
↗
February 26, 2026
TG Therapeutics (TGTX) Q4 2025 Earnings Transcript
Via
The Motley Fool
TG THERAPEUTICS INC (NASDAQ:TGTX) Q4 2025 Earnings Miss Estimates Despite Strong BRIUMVI Outlook
↗
February 26, 2026
Via
Chartmill
Topics
Earnings
Soleus Adds a Significant Number of Celcuity Shares
↗
February 13, 2026
This clinical-stage biotech develops targeted cancer therapies and diagnostics using proprietary technology for personalized treatment.
Via
The Motley Fool
TG Therapeutics Lights Up Super Bowl With Christina Applegate MS Campaign — Retail Sees 'Huge Win'
↗
February 09, 2026
TG Therapeutics reported that six-year data showed nearly 90% of patients on continuous Briumvi remained free of disability progression.
Via
Stocktwits
Hussman Strategic Advisors Sells 126,000 TG Therapeutics Shares
↗
February 02, 2026
This commercial-stage biotech develops therapies for B-cell malignancies and autoimmune diseases, leveraging a diverse clinical pipeline.
Via
The Motley Fool
TG Therapeutics Stock Pops As Briumvi Boom Reignites Bull Case: Goldman Sachs Sees Room For 32% Rally
↗
January 15, 2026
Via
Stocktwits
TG Therapeutics Stock Soars After Company Ups Guidance For Multiple Sclerosis Drug
↗
November 03, 2025
Via
Stocktwits
Earnings Scheduled For November 3, 2025
↗
November 03, 2025
Via
Benzinga
Earnings Preview For TG Therapeutics
↗
October 31, 2025
Via
Benzinga
TG Therapeutics Board Authorizes New $100M Share Repurchase Program
↗
September 03, 2025
Via
Stocktwits
Retail Traders Are Piling Into TG Therapeutics – What’s Driving The Chatter?
↗
January 14, 2026
On Tuesday, the company provided the revenue outlook for 2026 and fourth-quarter (Q4) and fiscal year 2025 revenue projection for BRIUMVI.
Via
Stocktwits
Topics
Artificial Intelligence
TGTX Rallies 7% After Hours On Revenue Estimates Based On Strong Briumvi Demand Through 2026
↗
January 13, 2026
The company expects total revenue for full year 2025 to be about $616 million, including $594 million from sales of its Briumvi in the U.S.
Via
Stocktwits
Topics
Artificial Intelligence
These stocks are moving in today's after hours session
↗
January 13, 2026
Via
Chartmill
TG Therapeutics TGTX Q3 2025 Earnings Transcript
↗
November 27, 2025
TG Therapeutics TGTX Q3 2025 Earnings Transcript
Via
The Motley Fool
10 Health Care Stocks With Whale Alerts In Today's Session
↗
November 11, 2025
Via
Benzinga
TG Therapeutics Crumbles After Roche Unveils Its 'Unprecedented' Test Results
↗
November 10, 2025
Roche presented "unprecedented" test results for its multiple sclerosis treatment, putting pressure on rival TG Therapeutics.
Via
Investor's Business Daily
Hussman Sells Off All 21,000 CHKP Shares Valued At $4.65 Million
↗
November 03, 2025
Hussman Sells Off All 21,000 CHKP Shares Valued At $4.65 Million
Via
The Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
↗
November 03, 2025
Via
Benzinga
Top Stocks With Earnings This Week: Joby, IonQ, AMD and More
↗
November 03, 2025
Retail investors are preparing for another busy week of earnings season with more than 1,600 companies set to report through Friday.
Via
Benzinga
Highly Watched TG Therapeutics Smashes Profit Views — With A Caveat
↗
November 03, 2025
TG Therapeutics stock rose early Monday on better-than-expected earnings.
Via
Investor's Business Daily
Topics
Earnings
Small-Cap Biotech Climb Bio's Lead Drug Candidate Has Larger Long-Term Opportunity
↗
October 16, 2025
William Blair assigns Climb Bio an Outperform rating, projecting peak sales of $1.9 billion and long-term growth for its therapy pipeline.
Via
Benzinga
TG THERAPEUTICS INC (NASDAQ:TGTX) Shows High Growth Momentum and Technical Breakout Setup
↗
October 07, 2025
TG Therapeutics (TGTX) shows explosive EPS growth up to 1,300% and strong sales momentum. With a perfect 10 technical rating and a bullish chart setup, it's a high-growth stock to watch.
Via
Chartmill
10 Health Care Stocks Whale Activity In Today's Session
↗
October 01, 2025
Via
Benzinga
TG Therapeutics CEO Voices Strong Conviction In Briumvi With New $100 Million Buyback
↗
September 03, 2025
TG Therapeutics' stock rose after completing a $100 million buyback and approving another $100 million plan, reinforcing confidence in Briumvi and growth prospects.
Via
Benzinga
TG Therapeutics Stock Tumbles 15% After Disappointing Q2, But Company Reaffirms Confidence In Multiple Sclerosis Drug
↗
August 04, 2025
The company raised its Briumvi U.S. net product revenue target to $570 million to $575 million for the full year 2025, up from its previous guidance of $560 million.
Via
Stocktwits
Topics
Earnings
Crude Oil Falls 1.5%; ON Semiconductor Shares Plunge After Q2 Results
↗
August 04, 2025
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
12
13
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
